Economic issues in coronary heart disease prevention.
The effectiveness of cholesterol lowering is well established, but cost-effectiveness is an increasing issue because of financial pressures on healthcare services. New statin studies have prospectively demonstrated that secondary prevention of coronary heart disease is almost always cost-effective, as is primary prevention in individuals at higher risk who have one or more other additional risk factors.